Last reviewed · How we verify
Faropenem(high dose group) — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Faropenem(high dose group) (Faropenem(high dose group)) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Faropenem(high dose group) TARGET | Faropenem(high dose group) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Faropenem(high dose group) CI watch — RSS
- Faropenem(high dose group) CI watch — Atom
- Faropenem(high dose group) CI watch — JSON
- Faropenem(high dose group) alone — RSS
Cite this brief
Drug Landscape (2026). Faropenem(high dose group) — Competitive Intelligence Brief. https://druglandscape.com/ci/faropenem-high-dose-group. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing